Avoid the stress of overpaying for a stock or missing an opportunity by using the right tools and insights to evaluate Inhibikase Therapeutics, Inc. before investing.

In this article, we go over a few key elements for understanding Inhibikase Therapeutics, Inc.’s stock price such as:

• Inhibikase Therapeutics, Inc.’s current stock price and volume
• Why Inhibikase Therapeutics, Inc.’s stock price changed recently
• Upgrades and downgrades for IKT from analysts
• IKT’s stock price momentum as measured by its relative strength

About Inhibikase Therapeutics, Inc. (IKT)

Before we jump into Inhibikase Therapeutics, Inc.’s stock price, history, target price and what caused it to recently rise, let’s take a look at some background.

Inhibikase Therapeutics, Inc. operates as a clinical-stage pharmaceutical company that develops therapeutics for Parkinson’s disease and related disorders. Its lead product candidate is IkT-148009, a non-receptor Abelson tyrosine kinase inhibitor, which is in Phase 2a clinical trials to the treatment of Parkinson’s disease and gastrointestinal tract. The company is also developing IkT-001Pro, a prodrug of the anticancer agent imatinib mesylate to treat stable phase chronic myelogenous leukemia. Inhibikase Therapeutics, Inc. has research and development collaborations with Johns Hopkins University, Arizona State University, and Michigan State University; and a collaborative research and development agreement with Sphaera Pharma Pte. Ltd. The company was founded in 2008 and is based in Atlanta, Georgia.

Want to learn more about Inhibikase Therapeutics, Inc.’s stock? Click the button below to subscribe to A+ Investor and get access to everything you need to know about Inhibikase Therapeutics, Inc..

Inhibikase Therapeutics, Inc.’s Stock Price as of Market Close

As of March 27, 2026, 4:00 PM, CST, Inhibikase Therapeutics, Inc.’s stock price was $1.680.

Inhibikase Therapeutics, Inc. is up 3.07% from its previous closing price of $1.630.

During the last market session, Inhibikase Therapeutics, Inc.’s stock traded between $1.620 and $1.760. Currently, there are approximately 132.03 million shares outstanding for Inhibikase Therapeutics, Inc..

Inhibikase Therapeutics, Inc.’s trailing earnings per share are negative, so the stock does not have a meaningful P/E ratio. We suggest investors evaluate other financial metrics to understand its overall valuation.

Inhibikase Therapeutics, Inc. Stock Price History

Inhibikase Therapeutics, Inc.’s (IKT) price is currently down 18.05% so far this month.

During the month of March, Inhibikase Therapeutics, Inc.’s stock price has reached a high of $2.080 and a low of $1.570.

Over the last year, Inhibikase Therapeutics, Inc. has hit prices as high as $2.390 and as low as $1.330. Year to date, Inhibikase Therapeutics, Inc.’s stock is down 18.05%.

Sign Up to Receive a Free Special Report Showing How A+ Grades Can Help You Make Smarter Investment Decisions

What Caused Inhibikase Therapeutics, Inc. Stock’s Price to Rise?

Stock prices are primarily based on seller supply and buyer demand. But have you ever wondered about what other factors affect a stock's price?

When an analyst changes their opinion of a stock by upgrading or downgrading their rating, it often leads to a sudden stock price adjustment. As of March 27, 2026, there were analysts who downgraded Inhibikase Therapeutics, Inc.’s stock and analysts who upgraded over the last month.

Additionally, you'll want to evaluate Inhibikase Therapeutics, Inc.’s financial health and valuation. Investors can use AAII's Value Grade, which combines six key valuation metrics like P/E and P/S ratios for a comprehensive analysis to conduct analysis on Inhibikase Therapeutics, Inc.’s valuation and financial health. This approach mitigates the limitations of single-metric evaluations.

Learn how to evaluate stocks with AAII Grades and Scores with A+ Investor today.

Lastly, news and media coverage as well as recent press reports about the company or its industry may cause stock prices to fluctuate. You can check out the most recent news articles about Inhibikase Therapeutics, Inc. (IKT) by visiting AAII Stock Evaluator.

Relative Price Strength of Inhibikase Therapeutics, Inc.

Relative price strength measures a stock's performance against the market, helping investors identify stocks that are outperforming benchmarks.

For AAII’s Momentum Grade, a weighted relative price strength is calculated. Follow this link to learn more about the Momentum Grade.

As of March 27, 2026, Inhibikase Therapeutics, Inc. has a weighted four-quarter relative price strength of -8.30%, which translates to a Momentum Score of 25 and is considered to be Weak.

Want to learn more about how Inhibikase Therapeutics, Inc. is graded based on AAII’s composite scores for value, growth, quality and earnings estimate revisions? Subscribe to A+ Investor today.

Inhibikase Therapeutics, Inc. Stock Price: Bottom Line

As of March 27, 2026, Inhibikase Therapeutics, Inc.’s stock price is $1.680, which is up 3.07% from its previous closing price.

AAII advises against making stock decisions based solely on price or past returns. Instead, consider a variety of metrics, fundamentals, and analytics to evaluate a stock like Inhibikase Therapeutics, Inc. stock prices are influenced by market supply and demand and offer just a snapshot of a company's overall health.

Subscribing to AAII's A+ Investor provides access to comprehensive analytics and insights for confident investing.